Charles Newton
Directeur Financier/CFO chez LYELL IMMUNOPHARMA, INC.
Fortune : 90 418 $ au 30/04/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Richard Klausner | M | 72 | 6 ans | |
| Heather Turner | F | 51 |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 5 ans |
| Chip Baird | M | 52 | - | |
| Nick Leschly | M | 51 | 3 ans | |
| Catherine Friedman | F | 63 | 20 ans | |
| Denny Lanfear | M | 68 | 14 ans | |
| Lynn Seely | M | 65 | 3 ans | |
| Daniel Lynch | M | 65 | 3 ans | |
| Stig Hansen | M | 59 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 16 ans |
| Daniel Simkowitz | M | 57 | 24 ans | |
| Timothy Kutzkey | M | 49 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 14 ans |
| Jeff Brodsky | M | 59 | 14 ans | |
| James Gorman | M | 65 | 18 ans | |
| Jill O'Donnell-Tormey | M | 68 | 2 ans | |
| Ellen Rose | F | - | 3 ans | |
| Frederick Pollock | M | 44 | 18 ans | |
| Matthew Lang | M | 48 | 1 ans | |
| Mark Stolper | M | 52 | 3 ans | |
| Aetna Wun Trombley | M | 45 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 8 ans |
| Denice Torres | F | 64 | 3 ans | |
| Sarah Glickman | F | 54 | 3 ans | |
| Wei Lin | M | 63 | 1 ans | |
| Kimberly Commins-Tzoumakas | F | 56 | 4 ans | |
| Marcela Maus | M | 48 | 3 ans | |
| Jenn Snyder | M | - | - | |
| Kelly Boothe | M | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | - |
| Stephen Hill | M | 53 | 5 ans | |
| Teresa Jurgensen | F | - | - | |
| Bryan Mcmichael | M | 46 | 3 ans | |
| Michael A. Fleming | M | - | 10 ans | |
| Elizabeth Nabel | M | 72 | 3 ans | |
| Minako Pazdera | M | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 ans |
| Ali Satvat | M | 46 | 10 ans | |
| Michael Gray | M | 53 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 ans |
| Otis Brawley | M | 64 | 3 ans | |
| William Rieflin | M | 64 | 4 ans | |
| Peter Svennilson | M | 62 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 4 ans |
| Robert Nelsen | M | 60 | 6 ans | |
| Lee Newcomer | M | 71 | 2 ans | |
| Timothy Garnett | - | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 ans |
| Hans Bishop | M | 59 | 6 ans | |
| Eric Grossman | M | 57 | 18 ans | |
| Anne Phillips | M | 70 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 ans |
| Timothy Garnett | M | 63 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 ans |
| Mats Wahlström | M | 70 | 12 ans | |
| James Howland | M | - | 16 ans | |
| Jonathan Starbecker | M | - | 18 ans | |
| Richard L. Hameister | M | - | 3 ans | |
| Heidi Brumbach | F | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 ans |
| Susan Abu-Absi | M | - | - | |
| Steven H. Bernstein | M | - | 2 ans | |
| Paul Reider | M | 55 | 3 ans | |
| Karen Kotz | F | - | 2 ans | |
| Morgan Adams | M | - | - | |
| Theresa M. LaVallee | M | 57 | 3 ans | |
| Rosh Dias | M | - | 2 ans | |
| Manu Chakravarthy | M | 50 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 3 ans |
| Richard D. Goold | M | 64 | 5 ans | |
| Gary Lee | M | 47 | 2 ans | |
| Rebecca Sunshine | F | 61 | 10 ans | |
| Kathy Bergsteinsson | F | - | 19 ans | |
| Elizabeth Pingpank | F | - | - | |
| Michael Ryan | M | - | 1 ans | |
| Katy L. Huberty | F | - | 24 ans | |
| David H. Schubert | M | - |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | - |
| Taylor Henricks | M | - | 17 ans | |
| Georgia Erbez | F | 57 | - | |
| Frank Ducomble | M | - | 18 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Jonathan Pruzan | M | 55 | 18 ans | |
| Elizabeth Homans | F | 58 | - | |
| Robert Scott | M | 78 | 2 ans | |
| Thomas R. Nides | M | 63 | 5 ans | |
| McDavid Stilwell | M | 53 | 3 ans | |
| Edward A. Brennan | M | 90 | - | |
| Thomas Kelleher | M | 67 | 15 ans | |
| Orin Port | M | - | 9 ans | |
| Sherrese Soares | F | 47 | 10 ans | |
| Vladimir Vexler | M | 66 | 10 ans | |
| Carl G Bauer-Schlichtegroll | M | - |
Credit Suisse Group AG /US/
 Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | 3 ans |
| Myles Lambert | M | 49 | 4 ans | |
| Dame Amelia Fawcett | F | 67 | 16 ans | |
| Robert Stockton | M | - | 1 ans | |
| Nadav Zohar | M | 59 | 7 ans | |
| John Carl Hahn | M | 65 | 11 ans | |
| Kevin Mailender | M | 46 | - | |
| Jaime Sanchez Yarza | M | - | - | |
| Charles Phillips | M | 64 | 4 ans | |
| James Rosenthal | M | 70 | 8 ans | |
| Donald T. Nicolaisen | M | 79 | 11 ans | |
| Gary W. Parr | M | 67 | 9 ans | |
| Hutham Olayan | F | 69 | 15 ans | |
| Philip J. Purcell | M | 80 | 19 ans | |
| Laura Tyson | M | 76 | 19 ans | |
| Robert Wood Jones | M | 73 | 32 ans | |
| Carroll A. Reddic | M | 58 | 14 ans | |
| Gary G. Lynch | M | 73 | 5 ans | |
| Raymond A. Harris | M | 67 | - | |
| Howard Davies | M | 73 | - | |
| Klaus Svendsen | M | - | 3 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 99 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Charles Newton
- Réseau Personnel